Kuan Arthur purchased $2.4M of CGON

Kuan Arthur (Chief Executive Officer) purchased 30,000 shares of CG Oncology, Inc. (CGON) at $78.88 ($2.37M total) on 2026-11-18.

Original reporting
SEC EDGAR · Kuan Arthur
Published Nov 18, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGON
Bullish
medium confidence
Mentioned
$CGON
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGONBullishLow
01

Why it matters

This provides a fresh datapoint on insider behavior, but it does not include any new operational, financial, or regulatory information that would directly re-rate the company’s fundamentals.

02

Market read

Traders may treat the insider buy as a small sentiment input, but the lack of accompanying company-specific catalysts limits tradable impact.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but the article does not provide intent, timing constraints, or whether the purchase was part of a broader pattern.

Relevance 7/10Novelty 6/10Timing: filed 2026-11-18, after-hours SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction for CG Oncology, Inc., reporting a CEO open-market purchase.

Company-level read

Ticker impact

$CGONBullishMedium confidence
Context

CEO Kuan Arthur filed a Form 4 open-market purchase of 30,000 CG Oncology shares at $78.8800 on 2026-11-18.

Expected impact

Likely limited near-term impact, with any reaction more sentiment-driven than fundamentals-driven.

Evidence & confidence

The disclosure is a primary Form 4 insider transaction, but it is not tied to guidance, earnings, deals, or regulatory outcomes in the article.

Market effects

Minimal, as the article provides only an insider transaction without sector-wide regulatory or clinical developments.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification activity and may not reflect a change in business outlook.

Key entities

  • CG Oncology, Inc.

    Subject of the Form 4 insider transaction, ticker CGON.

  • Kuan Arthur

    CEO and officer/director who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGONMed

CG Oncology Stock Falls 7% as RBC Downgrade Cools Rally After Bladder Cancer Drug Cuts Recurrence Risk by 68%

CG Oncology Inc. shares fell 7.53% on Tuesday, after a 14% rise on Monday following positive trial results for its bladder cancer treatment. RBC downgraded the stock to Sector Perform, citing regulatory path, despite raising its price target to $97. The Phase 3 trial showed a 68% reduction in cancer recurrence risk. Other analysts raised price targets, with JPMorgan at $113 and Truist at $100.

$CGONMed

Truist raises CG Oncology stock price target on trial results

Truist Securities raised its price target for CG Oncology (CGON) to $100 from $85, citing positive PIVOT-006 trial results. The stock is up 16.7% over the past week. Full data will be presented in December 2026, with FDA submissions expected in 2027. Analysts have revised earnings estimates upward, highlighting a multi-billion-dollar market opportunity.

$CGONMed

JPMorgan raises CG Oncology stock price target on trial data

JPMorgan raised its price target for CG Oncology (CGON) to $113 from $96, citing positive trial data and regulatory updates. The stock, currently at $84.78, has surged over 104% year-to-date. JPMorgan increased its success probability for Creto in bladder cancer treatments, projecting $1.2B and $1.0B in U.S. peak sales by 2037 for different settings. RBC Capital downgraded CGON to Sector Perform but raised its target to $97.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.